Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine Glucuronide SCHEMBL6754812 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL17302928 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL152647 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL12082244 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL1743681 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13267437 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13268600 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL13245908 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL5674614 | 0.99 | OPRM1 (0.98) | OPRM1MRGPRX2OPRD1OPRK1 | |
| Morphine Glucuronide SCHEMBL5674692 | 0.97 | OPRM1 (0.94) | OPRM1MRGPRX2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884029-B2 | Morphine controlled release system | EGALET LTD. (GB) | 2018-02-06 | — | — | US | claimed |
| EP-1912658-B1 | THERAPEUTIC PROTOCOLS USING HYALURONAN | ALCHEMIA ONCOLOGY PTY LTD (AU) | 2017-01-25 | — | — | EP | claimed |
| US-20160361269-A1 | MORPHINE CONTROLLED RELEASE SYSTEM | EGALET LTD. (GB) | 2016-12-15 | — | — | US | claimed |
| US-9375428-B2 | Morphine controlled release system | EGALET LTD. (GB) | 2016-06-28 | — | — | US | claimed |
| EP-2301526-B1 | Morphine controlled release system | EGALET LTD (GB) | 2016-03-23 | — | — | EP | claimed |
| US-20150343054-A1 | Heroin Haptens, Immunoconjugates and Related Uses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-03 | — | — | US | claimed |
| US-20150079150-A1 | MORPHINE CONTROLLED RELEASE SYSTEM | EGALET LTD. (GB) | 2015-03-19 | — | — | US | claimed |
| EP-2844733-A1 | IN VITRO MODEL FOR PATHOLOGICAL OR PHYSIOLOGIC CONDITIONS | Hemoshear, LLC (US) | 2015-03-11 | — | — | EP | claimed |
| CN-104350142-A | In vitro model for pathological or physiologic conditions | HEMOSHEAR LLC | 2015-02-11 | — | — | CN | claimed |
| US-8877241-B2 | Morphine controlled release system | EGALET LTD. (GB) | 2014-11-04 | — | — | US | claimed |
| WO-2003082215-A2 | SYNERGISTIC L-METHADONE COMPOSITIONS AND METHODS OF USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2003-10-09 | — | — | WO | claimed |
| WO-2003080066-A1 | USE OF DEVAZEPIDE FOR THE TREATMENT OF CONSTIPATION | ML LABORATORIES PLC (GB) | 2003-10-02 | — | — | WO | claimed |
| WO-2003024430-A1 | MORPHINE POLYMER RELEASE SYSTEM | EGALET A/S (DK) | 2003-03-27 | — | — | WO | claimed |
| EP-1276475-A2 | TOPICAL ANESTHETIC/OPIOID FORMULATIONS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2003-01-22 | — | — | EP | claimed |
| WO-2001082914-A2 | TOPICAL ANESTHETIC/OPIOID FORMULATIONS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001043528-A2 | DEVICES AND METHODS IN INTRACEREBROSPINAL DELIVERY OF MORPHINE-6-GLUCURONIDE | DURECT CORPORATION (US) | 2001-06-21 | — | — | WO | claimed |
| EP-1102589-A1 | TOPICAL COMPOSITIONS COMPRISING AN OPIOID ANALGESIC AND AN NMDA ANTAGONIST | MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2001-05-30 | — | — | EP | claimed |
| WO-2000003716-A1 | TOPICAL COMPOSITIONS COMPRISING AN OPIOID ANALGESIC AND AN NMDA ANTAGONIST | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2000-01-27 | — | — | WO | claimed |
| EP-0895473-A1 | POLYSACCHARIDE MICROSPHERES FOR THE PULMONARY DELIVERY OF DRUGS | DANBIOSYST UK LIMITED (GB) | 1999-02-10 | — | — | EP | claimed |
| WO-1997035562-A1 | POLYSACCHARIDE MICROSPHERES FOR THE PULMONARY DELIVERY OF DRUGS | DANBIOSYST UK LIMITED (GB) | 1997-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150343054-A1 | Heroin Haptens, Immunoconjugates and Related Uses | OPRM1, CXCR5, OPRK1 | OPRM1 1/4885MRGPRX2 428/4885OPRD1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.